RTP Mobile Logo
Meet The Professors: Investigators Present Current Cases from Their Practices and Discuss Relevant Recent Data Sets
Released July 2014

Proceedings from a daylong symposium featuring key clinical presentations and papers in breast cancer, myeloid cancers, multiple myeloma and Hodgkin and non-Hodgkin lymphomas, including chronic lymphocytic leukemia. Including perspectives from Drs Adam M Brufsky, Joyce O’Shaughnessy, Moshe Talpaz, B Douglas Smith, Hagop M Kantarjian, Andrzej J Jakubowiak, Joseph Mikhael, John P Leonard, Craig Moskowitz and Christopher Flowers. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    OVERVIEW OF ACTIVITY
    Clinical controversies and uncertainties persist in the management of many common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published in peer-reviewed journals. This continual influx of information challenges practicing healthcare professionals to stay up to date and abreast of crucial data applicable in clinical practice. To that end, these proceedings from a daylong symposium deliver the perspectives of 10 renowned investigators on recent presentations and publications, including those unveiled during the 2013 American Society of Hematology (ASH) Annual Meeting and San Antonio Breast Cancer Symposium, to provide insight into the current and future management of breast cancer, myeloid cancers, multiple myeloma and Hodgkin and non-Hodgkin lymphomas, including chronic lymphocytic leukemia.

    LEARNING OBJECTIVES

    • Apply emerging clinical trial data to the best-practice care of patients with early and advanced breast cancer.
    • Appraise recent data on therapeutic advances and changing practice standards in multiple myeloma, and refine or validate existing treatment algorithms based on discussion of this information.
    • Integrate existing and recently approved therapeutic strategies into the management of non-Hodgkin and Hodgkin lymphomas.
    • Apply the results of emerging research information to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory chronic lymphocytic leukemia.
    • Individualize the treatment of acute leukemias, myeloproliferative disorders and myelodysplastic syndromes, considering patient- and disease-specific factors.
    • Assess the ongoing clinical trials evaluating innovative investigational approaches for the aforementioned cancer types, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Adam M Brufsky, MD, PhD
    Professor of Medicine, University of Pittsburgh
    Associate Director for Clinical Investigation
    University of Pittsburgh Cancer Institute
    Co-Director, Comprehensive Breast Cancer Center
    Associate Division Chief
    University of Pittsburgh Department of Medicine
    Division of Hematology/Oncology
    Pittsburgh, Pennsylvania

    Consulting Agreements: Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    Joyce O’Shaughnessy, MD
    Co-Director, Breast Cancer Research Program
    Baylor-Charles A Sammons Cancer Center
    Texas Oncology
    US Oncology
    Dallas, Texas

    Consulting Agreements: Celgene Corporation, Corcept Therapeutics, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Lilly, Merrimack Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    Moshe Talpaz, MD
    Alexander J Trotman Professor for Leukemia Research
    Associate Director for Translational Research, UMCCC
    Co-Director, Hematologic Malignancies/BMT Program, UMCCC
    University of Michigan Hospital and Health Systems
    Ann Arbor, Michigan

    Advisory Committee: ARIAD Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Consulting Agreement: Pfizer Inc; Contracted Research: Abbott Laboratories, ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Sanofi.

    B Douglas Smith, MD
    Associate Professor of Oncology
    Division of Hematologic Malignancies
    The Sidney Kimmel Comprehensive Cancer
    Center at Johns Hopkins
    Baltimore, Maryland

    Consulting Agreements: ARIAD Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Teva Oncology.

    Hagop M Kantarjian, MD
    Chairman and Professor, Leukemia Department
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No real or apparent conflicts of interest to disclose.

    Andrzej J Jakubowiak, MD, PhD
    Professor of Medicine
    Director, Myeloma Program
    The University of Chicago
    Chicago, Illinois

    Advisory Committee: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Onyx Pharmaceuticals Inc.

    Joseph Mikhael, MD, MEd
    Associate Dean, Mayo School of Graduate
    Medical Education
    Deputy Director - Education
    Mayo Clinic Cancer Center
    Associate Professor, Mayo College of Medicine
    Mayo Clinic in Arizona
    Scottsdale, Arizona

    Contracted Research: Celgene Corporation, Onyx Pharmaceuticals Inc, Sanofi.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Biotest Pharmaceuticals Corporation, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Hospira Inc, Johnson & Johnson Pharmaceuticals, MedImmune Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology.

    Craig Moskowitz, MD
    Clinical Director, Division of Hematologic Oncology
    Attending Physician, Lymphoma and Adult BMT Services
    Member, Memorial Sloan-Kettering Cancer Center
    Professor of Medicine, Weill Medical College of Cornell University
    New York, New York

    Advisory Committee: GlaxoSmithKline, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Cephalon Inc, GlaxoSmithKline, Roche Laboratories Inc, Seattle Genetics; Paid Research: Plexxikon Inc.

    Christopher Flowers, MD, MS
    Associate Professor of Hematology and Medical Oncology
    Emory School of Medicine Winship Cancer Institute
    Atlanta, Georgia

    Advisory Committee: Biogen Idec, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Algeta ASA, Celgene Corporation, OptumRx Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, Incyte Corporation, Lilly, Onyx Pharmaceuticals Inc, Seattle Genetics and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2014
    Expiration date: July 2015

Acknowledge and close

View video: